In this context, we conclude that a promising therapeutic strategy for CRC patients may be based on genetic mutation detections and targeting either EGFR/VEGFR in association with PI3K/AKT/mTOR, Wnt/β-catenin, or MAPK inhibitors. Here, MTOR is linked to colorectal carcinoma.